GS-US-595-6184 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63; NCT05633654)
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
Gilead Sciences, Inc.